Pfizer Inc. (NYSE:PFE) Receives Average Rating of “Hold” from Analysts

Shares of Pfizer Inc. (NYSE:PFE) have received a consensus rating of “Hold” from the twenty-three analysts that are covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a sell recommendation, fourteen have assigned a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $28.0476.

Several analysts have issued reports on PFE shares. Bank of America dropped their price target on Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research note on Monday, December 15th. Royal Bank Of Canada assumed coverage on Pfizer in a research report on Tuesday, February 24th. They set an “underperform” rating and a $25.00 price objective for the company. TD Cowen reiterated a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. Citigroup started coverage on Pfizer in a research note on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 target price on the stock. Finally, HSBC reaffirmed a “buy” rating and set a $29.00 price target on shares of Pfizer in a research report on Wednesday, December 10th.

Pfizer Stock Performance

Shares of PFE stock opened at $27.12 on Wednesday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. Pfizer has a 52 week low of $20.92 and a 52 week high of $27.94. The company’s 50 day moving average price is $26.38 and its two-hundred day moving average price is $25.49. The company has a market capitalization of $154.22 billion, a P/E ratio of 19.94 and a beta of 0.47.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. The business had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm’s quarterly revenue was down 1.2% on a year-over-year basis. During the same period last year, the business posted $0.63 earnings per share. On average, analysts expect that Pfizer will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, March 6th. Investors of record on Friday, January 23rd were issued a dividend of $0.43 per share. The ex-dividend date was Friday, January 23rd. This represents a $1.72 annualized dividend and a yield of 6.3%. Pfizer’s dividend payout ratio is presently 126.47%.

Institutional Investors Weigh In On Pfizer

Several institutional investors and hedge funds have recently added to or reduced their stakes in PFE. Brighton Jones LLC grew its stake in Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after purchasing an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC raised its stake in shares of Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after purchasing an additional 2,087 shares in the last quarter. United Bank boosted its holdings in shares of Pfizer by 12.4% in the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock valued at $1,408,000 after buying an additional 6,415 shares during the last quarter. Telos Capital Management Inc. boosted its holdings in shares of Pfizer by 9.2% in the 2nd quarter. Telos Capital Management Inc. now owns 27,400 shares of the biopharmaceutical company’s stock valued at $664,000 after buying an additional 2,314 shares during the last quarter. Finally, Westside Investment Management Inc. grew its stake in shares of Pfizer by 7.3% in the second quarter. Westside Investment Management Inc. now owns 17,714 shares of the biopharmaceutical company’s stock valued at $431,000 after buying an additional 1,205 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Positive Phase‑2 readout for tilrekimig (PF‑07275315) — the study met its primary endpoint (EASI‑75 at Week 16) and Pfizer plans late‑stage testing, which materially strengthens the company’s dermatology pipeline and future growth prospects. Pfizer’s Phase 2 Study of Trispecific Antibody Positive in Moderate-to-Severe Atopic Dermatitis Pfizer’s eczema drug meets main goal in mid-stage trial
• Neutral Sentiment: FDA approved leucovorin for a rare genetic condition but not for autism — important regulatory news for the sector but not directly tied to Pfizer’s marketed products or near‑term revenue. FDA Approves Leucovorin—But Not For Autism
• Neutral Sentiment: Patent activity around tafamidis (a competing transthyretin amyloidosis drug) and related market moves lifted other small caps — the BridgeBio story signals shifting patent dynamics that could influence competitive positioning over time but the impact on Pfizer is uncertain. Why BridgeBio Leapfrogged Its 50-Day Line On Pfizer’s Patent Shake-Up
• Neutral Sentiment: BioNTech cofounders stepping down rattled biotech sentiment broadly; this is sector noise that can increase volatility but does not directly affect Pfizer’s fundamentals. BioNTech Cofounders To Step Down. Stock Crumbles.
• Negative Sentiment: Investor concern over Pfizer’s payout ratio (reported >100%) and a quarterly loss raised the specter of dividend pressure — this remains a key negative risk that can cap upside and prompt selling. Pfizer’s Payout Ratio Is Still Over 100%. Is a Dividend Cut Inevitable?
• Negative Sentiment: Despite the positive eczema data, some reports noted shares dipped earlier — signaling profit‑taking and investor skepticism that new pipeline data will immediately translate to material revenue. That caution can mute sustained rallies. Pfizer shares dip despite positive trial results for skin condition drug

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.